Comparing Deciphera Pharmaceuticals (DCPH) & The Competition
Deciphera Pharmaceuticals (NASDAQ: DCPH) is one of 286 public companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its competitors? We will compare Deciphera Pharmaceuticals to similar businesses based on the strength of its dividends, risk, valuation, profitability, earnings, institutional ownership and analyst recommendations.
Valuation & Earnings
This table compares Deciphera Pharmaceuticals and its competitors gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Deciphera Pharmaceuticals||N/A||-$25.94 million||N/A|
|Deciphera Pharmaceuticals Competitors||$284.28 million||$34.29 million||73.44|
Deciphera Pharmaceuticals’ competitors have higher revenue and earnings than Deciphera Pharmaceuticals.
Institutional and Insider Ownership
43.9% of Deciphera Pharmaceuticals shares are held by institutional investors. Comparatively, 50.2% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 17.1% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
This is a breakdown of current ratings and target prices for Deciphera Pharmaceuticals and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Deciphera Pharmaceuticals Competitors||857||3201||11604||231||2.71|
Deciphera Pharmaceuticals presently has a consensus price target of $43.40, suggesting a potential upside of 138.33%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 43.67%. Given Deciphera Pharmaceuticals’ stronger consensus rating and higher possible upside, equities analysts plainly believe Deciphera Pharmaceuticals is more favorable than its competitors.
This table compares Deciphera Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Deciphera Pharmaceuticals Competitors||-5,313.56%||-219.98%||-40.02%|
Deciphera Pharmaceuticals beats its competitors on 6 of the 11 factors compared.
About Deciphera Pharmaceuticals
Deciphera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing drugs to improve the lives of cancer patients. Its drug candidate includes DCC-2618, DCC-3014 and Rebastinib. Its proprietary kinase switch control inhibitor platform, inhibit the activation of kinases. DCC-2618, an orally administered kinase switch control inhibitor, for the treatment of gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, including glioblastoma multiforme (GBM), and other solid tumors driven by pan-KIT or PDGFR alpha. DCC-3014 is an orally administered, potent and highly selective inhibitor of colony stimulating factor receptor 1 (CSF1R). Rebastinib is an orally administered, potent and selective inhibitor of the TIE2 immunokinase. Rebastinib binds potently into the switch pocket of TIE2, stabilizing the inhibitory switch and displacing the activation switch to block TIE2 signaling.
Receive News & Ratings for Deciphera Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.